fda compounded semaglutide enforcement news The says it's standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly's diabetes and weight loss drugs Mounjaro and Zepbound — is over Finally, there’s good news in

Over-expression of Slc30a8/ZnT8 selectively in the mouse cell impairs glucagon release and responses to hypoglycemia

The self-insured part of the employer market is more likely to cover GLP-1s, since employers may feel pressure to cover the medications, and because the tenure of workers is generally longer in larger self-insured companies

Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis [see Warnings and Precautions (5.2), and Adverse Reactions (6)]

Powers MA, Bardsley J, Cypress M et al (2015) Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics